Please login to the form below

Not currently logged in
Email:
Password:

Cell Therapeutics

This page shows the latest Cell Therapeutics news and features for those working in and with pharma, biotech and healthcare.

MedCity sets up advanced therapy research network

MedCity sets up advanced therapy research network

The UK’s  life sciences hub MedCity has launched an initiative to foster greater collaboration between industry and academia in cell, tissue and gene therapies. ... UK companies operating int his area include university spinouts Orchard Therapeutics,

Latest news

More from news
Approximately 9 fully matching, plus 40 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    Joint development using SQZ’s cell therapy. platform. $1.375B. Option. Ionis. RNA‐ targeted therapeutics for complement mediated. ... Acquisition. $2B. Tango Therapeutics/. Gilead Sciences. Pipeline of up to 5 targeted immuno‐ oncology.

  • Deal Watch February 2017 Deal Watch February 2017

    Licence. 358. AstraZeneca/ TerSera Therapeutics. Zoladex, goserelin acetate implant for prostate, breast cancer, benign gynaecological disorders (marketed). ... Licence. 320. Lonza/ Sanofi. Large scale mammalian cell manufacturing facility for antibody

  • Deal Watch November 2016 Deal Watch November 2016

    One piece of unwelcome news this month was from Juno Therapeutics, which announced it had halted a phase 2 trial of JCAR015, its CAR T cell immunotherapeutic, in patients with relapsed ... This is despite some positive news for Juno released at the

  • Deal Watch February 2016 Deal Watch February 2016

    licence, collaboration expanded. 830. Adaptimmune Therapeutics/ GSK. TCR engineered T-cell therapies inc affinity enhanced T-cell immunotherapy targeting NY-ESO-1 (p1/2); 4 other progs and combination studies. ... acquisition - product. 190. Annapurna

  • Pharma deals in August 2015 Pharma deals in August 2015

    Recent deals: acquired Chatham Therapeutics [$70m]; collaboration Coherus Biosciences, divested vaccines to Pfizer [$625m], global licence Cell Therapeutics for pacritinib. ... Acquisition of Priority Review Voucher. 350. Evotec. Sanofi. Beta cell

More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest appointments

  • Gamida Cell strengthens leadership team Gamida Cell strengthens leadership team

    Cellular and immune therapeutics group Gamida Cell has appointed a new chief business officer in the form of Josh Hamermesh. ... Alongside Hamermesh, Gamida Cell has appointed Paul Nee (pictured left) as its vice president of marketing.

  • Rubius Therapeutics adds to its board of directors Rubius Therapeutics adds to its board of directors

    Rubius Therapeutics adds to its board of directors. Francis Cuss and Catherine Sohn join the US biotech. ... Alongside Cuss, Catherine Sohn, currently non-executive chairman of BioEclipse Therapeutics, has also joined the biotech’s board.

  • Rubius Therapeutics strengthens senior team Rubius Therapeutics strengthens senior team

    Rubius Therapeutics, a company focused on creating Red-Cell Therapeutics, has bolstered its senior team with the addition of four new hires. ... Chris and the rest of the team will play a pivotal role in bringing the promise of red cell therapeutics to

  • Bone Therapeutics strengthens clinical development team Bone Therapeutics strengthens clinical development team

    Bone Therapeutics strengthens clinical development team. Dr Miguel Forte joins the firm as chief medical officer. ... Thomas Lienard, chief executive officer at Bone Therapeutics, said: “His vast expertise in cell therapy will be a strong asset to our

  • David Epstein joins Flagship Pioneering as executive partner David Epstein joins Flagship Pioneering as executive partner

    In this newly-created position, Epstein will begin working with Rubius Therapeutics, a red blood cell-focused exploratory venture within the Flagship portfolio, as chairman of its board.

More from appointments
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest from PMHub

  • mRNA vaccines & therapeutics Market to Hit USD 920 million by 2023

    Cancer is yet another prominent application fueling the mRNA vaccines &therapeutics market size. ... Market Segment by Manufacturers, this report covers. Moderna Therapeutics, CureVac, Translate Bio, BioNTech, Sangamo Therapeutics, Argos Therapeutics,

  • Training the next generation of biotech leaders

    Training the next generation of biotech leaders. Cell and gene therapy is no longer science fiction. ... society. “ We look at the manufacturing challenges we are facing for emerging healthcare products, such as stratified protein therapeutics and

  • Oncology drugs under AMNOG

    Pixuvri: Polycomparator segmentation by the G-BA removes statistical power. Cell Therapeutics gained European approval for Pixuvri (pixantrone) in non-Hodgkin’ s B-cell lymphoma, on the basis of a trial

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
BASTARD . LONDON

BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...

Latest intelligence

Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
What everyone forgets about good organisational change in pharma
Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....
Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies
Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST...

Infographics